Pharmazie
Refine
Year of publication
Document Type
- Article (171) (remove)
Language
- English (171) (remove)
Has Fulltext
- yes (171)
Is part of the Bibliography
- no (171)
Keywords
- aging (4)
- inflammation (4)
- 5-lipoxygenase (3)
- BRD4 (3)
- cancer (3)
- proteomics (3)
- AML (2)
- Absorption (2)
- Alzheimer’s disease (2)
- Apoptosis (2)
- E2F-1 (2)
- HDAC (2)
- IKZF1 (2)
- Inflammation (2)
- MLL (2)
- MLL-r leukemia (2)
- PAD4 (2)
- PPARγ (2)
- Proteins (2)
- allostery (2)
- apoptosis (2)
- bromodomains (2)
- citrullination (2)
- cyclooxygenase (2)
- dissolution (2)
- epigenetics (2)
- immune response (2)
- lymphocytes (2)
- mitochondria (2)
- multiple sclerosis (2)
- neuropathic pain (2)
- oxidative stress (2)
- pain (2)
- presenilin-1 (2)
- reactive oxygen species (2)
- soluble epoxide hydrolase (2)
- transcription factor (2)
- transgenic mice (2)
- 1α,25(OH)2D3 (1)
- 2-deoxy-D-ribose (1)
- 5-Lipoxygenase (1)
- 5-Lipoxygenase activating protein (FLAP) (1)
- ABCB1 (1)
- AD patients (1)
- AF4 (1)
- API (1)
- APP processing (1)
- ARID5B (1)
- ATAD2 (1)
- Action Plan for Medication Safety (1)
- Activation markers (1)
- Acute leukemia (1)
- Aging (1)
- Alcoholic liver disease (1)
- Alpha-synuclein (1)
- Alzheimer's disease (1)
- Amyloid-beta (1)
- Anticancer therapy (1)
- Anticoagulation (1)
- Anticonvulsant activity (1)
- Arachidonic acid cascade (1)
- Autoimmune encephalomyelitis (1)
- Axons (1)
- BDNF (1)
- BRD2 (1)
- BROMO-10 (1)
- Bcl-2 (1)
- Binding analysis (1)
- Bioavailability (1)
- Biochemistry (1)
- Biomarkers & Diagnostic Imaging (1)
- Blood brain barrier (1)
- Boswellia serrata (1)
- Boswellic acids (1)
- Bromodomänen (1)
- CAR T cells (1)
- CD36 (1)
- CD4+ T lymphocytes (1)
- CD69 expression (1)
- CEBPE (1)
- CHRNA10 (1)
- CHRNA7 (1)
- CHRNA9 (1)
- CNS melanoma (1)
- COBL (1)
- CPTAC (1)
- CRC65 (1)
- CRM1 (1)
- Caco-2 cells (1)
- Calliphora (1)
- Cancer (1)
- Cancer cell migration (1)
- Cancer treatment (1)
- Cell adhesion (1)
- Cell binding (1)
- Cell biology (1)
- Cell cycle (1)
- Cell differentiation (1)
- Cell signalling (1)
- Cell staining (1)
- Cell therapy (1)
- Cerebral cortex (1)
- Cerebral ischemia (1)
- Chaperones (1)
- Chemical biology (1)
- Chemische Sonden (1)
- Chemoinformatics (1)
- Chlorides (1)
- Chromosomal translocations (1)
- Collagens (1)
- Complex II (1)
- Compound Database (1)
- Connectomics (1)
- Crystal structure (1)
- Curcumin micelles (1)
- Cyclic GMP (1)
- Cyclooxygenases (1)
- Cytokine expression (1)
- DDDPlus (1)
- DYRK1A (1)
- Dendritic structure (1)
- Diabetes mellitus (1)
- Dicer (1)
- Differential Scanning Calorimetry (DSF) (1)
- Diflapolin (1)
- Drosophila melanogaster (1)
- Drug discovery (1)
- Drug safety (1)
- E2F-responsive genes (1)
- EGR1/2/3 (1)
- ET-MP (1)
- Electron microscopy (1)
- Endothelial cells (1)
- Epigenetik (1)
- Erythropoiesis (1)
- Experimental autoimmune encephalomyelitis (1)
- Extracellular matrix (1)
- FGF-2 KO (1)
- FGFR (1)
- FRET imaging (1)
- Ficus carica (1)
- FlexTouch (1)
- Frankincense (1)
- Free energy (1)
- Gene (1)
- Gene expression (1)
- General practice (1)
- Genetic transduction (1)
- Germany (1)
- Glutathione reductase (1)
- Guanylyl cyclases (1)
- HDACi (1)
- HIV-1 (1)
- HOXA profile (1)
- HOXB4 (1)
- Hepatitis (1)
- High performance liquid chromatography (1)
- Hippocampus (1)
- Hydrogen bonding (1)
- IFN (1)
- IRX1 (1)
- IVIV_E (1)
- Identical Topology (1)
- Immunosenescence (1)
- Indoles (1)
- Infant leukemia (1)
- Integrins (1)
- Interleukin-22 (1)
- Intracerebroventricular (1)
- Isothermal Titration Calorimetry (ITC) (1)
- Kidney (1)
- Kinase inhibitors (1)
- Kinases (1)
- LASP1 (1)
- LTP (1)
- Lead Structure (1)
- Lecithin (1)
- Leishmania infantum (1)
- Leukotriene (1)
- Lipid peroxidation (1)
- Lipid raft (1)
- Liver cirrhosis (1)
- Liver-related complications (1)
- Lpar2 (1)
- Luciferase (1)
- Lymphocytes (1)
- Lysophosphatidic acids (1)
- MALDI MS (1)
- MAML2 (1)
- MEIS2 (1)
- MELD (1)
- MKP1 (1)
- MLL fusion proteins (1)
- MLV (1)
- MYC (1)
- Machine learning (1)
- Mechanisms of disease (1)
- Medication changes (1)
- Medizinische Chemie (1)
- Metabolic syndrome (1)
- Metabolism (1)
- Mice (1)
- Microbiology (1)
- Mitochondria (1)
- Mitochondrial dysfunction (1)
- Molecular association (1)
- Molecular docking (1)
- Molecular mechanisms of cancer (1)
- Molecular medicine (1)
- Moraceae (1)
- Motor neurons (1)
- Multimorbidity (1)
- Multiple chronic conditions (1)
- Mutant p53 (1)
- Myelopoiesis (1)
- NEBL (1)
- NFAT (1)
- NFκB (1)
- NMR Spectroscopy (1)
- NO-GC stimulators (1)
- Nano-ESI MS (1)
- Natriuretic peptides (1)
- Neurodegeneration (1)
- Neuroinflammation (1)
- Neuronal dendrites (1)
- Neurons (1)
- Neuroscience (1)
- Nitric oxide (1)
- Npr2 (1)
- Nrf2 (1)
- Older adults (1)
- Oxidative phosphorylation (1)
- Oxidative stress (1)
- P2X3 (1)
- P2X7 receptor (1)
- PBPK (1)
- PBX1 (1)
- PC12 cells (1)
- PGC-1 alpha (1)
- PPAR gamma activator (1)
- Pairwise Sequence Alignment (1)
- Parietal cortex (1)
- Parkinson’s disease (1)
- Pathogenesis (1)
- Pharmacodynamics (1)
- Phosphodiesterases (1)
- Physical and chemical properties (1)
- Polypharmacy (1)
- Presenilin (1)
- Proliferation (1)
- Purkinje cells (1)
- R software (1)
- RAG (1)
- RNA-templated DNA repair (1)
- RXRα (1)
- Reactive oxygen species (1)
- SAMHD1 knockout mouse (1)
- SAMHD1 phosphorylation (1)
- SAVI (1)
- SKNSH-SY5Y neuroblastoma cells (1)
- SMAD (1)
- SMAP1 (1)
- SSR128129E (1)
- STING (1)
- STK3 (1)
- Secondary mutations (1)
- Sequence motif analysis (1)
- Slack (1)
- Slack channel (1)
- SoloSTAR (1)
- Soluble epoxide hydrolase (sEH) (1)
- Spinal cord (1)
- Structure-based drug discovery (1)
- Strukturbasiertes Design (1)
- Superoxide dismutase (1)
- Synapses (1)
- T lymphocyte subsets (1)
- T-cell homing (1)
- T-cell targeting (1)
- TALE-homdomain protein (1)
- Target identification (1)
- Target validation (1)
- Tools and resources (1)
- Transcription factors (1)
- Transcriptional control (1)
- Transepithelial transport (1)
- Translocation partner genes (1)
- Triterpenoids (1)
- Tween 80 (1)
- Tyrosine phosphorylation (1)
- UCN-01 (1)
- VDR (1)
- Virtual Screening (1)
- Vision (1)
- Vitamin D (1)
- WT1 (1)
- Wnt (1)
- X-ray structure analysis (1)
- acute lymphoblastic leukemia (1)
- alzheimer’s disease (1)
- amorphous stability (1)
- amyloid precursor protein (1)
- amyloid precursor protein (APP) (1)
- analgesia (1)
- androgen receptor (1)
- anticonvulsants (1)
- antioxidants (1)
- axon bifurcation (1)
- axonal pathfinding (1)
- bioinformatics (1)
- biopharmaceutics (1)
- biorelevant media (1)
- biosimilar and analogue insulins (1)
- biosynthetic human insulin (1)
- blood–brain barrier (1)
- boswellic acid (1)
- bromodomain inhibitor (1)
- cGKI (1)
- cGMP (1)
- calcitriol (1)
- calcium (1)
- calcium-independent phospholipase A2β (1)
- caspase (1)
- castration-resistant prostate cancer (1)
- cathepsin (1)
- cell death (1)
- cerebellar granule cells (1)
- cerebral ischemia (1)
- chemical biology (1)
- chemical probes (1)
- cholesterol (1)
- chondrocytes (1)
- chromatin (1)
- chronobiology (1)
- citrate (1)
- cofactor recruitment (1)
- controlled nuclear import (1)
- cost (1)
- cyclodextrine (1)
- cytochrome c. (1)
- dalargin (1)
- data modeling (1)
- day time dependent transport (1)
- designed multitarget ligands (1)
- deubiquitylating enzymes (1)
- development (1)
- disintegration (1)
- disposable insulin pens (1)
- dissolution modeling (1)
- docosahexaenoic acid (1)
- dorsal root ganglia (1)
- dosing accuracy (1)
- drug resistance (1)
- drug response (1)
- drug target (1)
- drug–drug interaction (DDI) (1)
- eicosanoid (1)
- electrophiles (1)
- electrophysiology (1)
- endothelium (1)
- enhancer of transcription (1)
- enzyme mechanism (1)
- epigenetic (1)
- epilepsy (1)
- epileptic encephalopathies (1)
- epithelial cells (1)
- epithelium (1)
- extracellular matrix (1)
- fluorescence confocal laser scanning microscopy (1)
- fluorescent ligand (1)
- forkhead box protein o1 (1)
- frankincense (1)
- gene therapy (1)
- genes (1)
- genetic rearrangements (1)
- glass forming ability (1)
- global access (1)
- glucose (1)
- guanylyl cyclase (1)
- heterodimer (1)
- hippocampal neurons (1)
- hippocampus (1)
- homodimer (1)
- homogeneous time-resolved FRET (HTRF) (1)
- hotmelt extrusion (1)
- human histamine H3 receptor (1)
- hydroxysafflor yellow A (1)
- hyperalgesia (1)
- immortalized porcine brain microvascular endothelial cells (1)
- immunofluorescence (1)
- immunomodulation (1)
- in vitro in vivo extrapolation (IVIVE) (1)
- in vitro model (1)
- in vivo gene delivery (1)
- indole (1)
- indomethacin (1)
- inflammasome (1)
- inhibitor (1)
- innate immune system (1)
- interleukin-1β (1)
- interleukin-2 gene (1)
- interleukins (1)
- isoforms (1)
- ketoconazole (1)
- ketone bodies (1)
- lactate (1)
- leukemia; solid tumors (1)
- leukocyte-endothelial cell interaction (1)
- levetiracetam (1)
- loxapine (1)
- lymphocyte (1)
- mPGES-1 (1)
- mass spectrometry (1)
- mechanistic oral absorption modeling (1)
- medication plan (1)
- medication schedule (1)
- medicinal chemistry (1)
- membrane fluidity (1)
- membrane transport (1)
- mesoporous silica (1)
- metabolic syndrome (1)
- miRNA in immune cells (1)
- mice (1)
- microsomal prostaglandin E2 synthase (1)
- middle cerebral artery occlusion (1)
- mitochondrial dysfunction (1)
- mitosis (1)
- model fitting (1)
- molecular docking (1)
- molecular marker (1)
- molecular mechanisms (1)
- montelukast (1)
- mouse (1)
- nanoparticles (1)
- nephelometry (1)
- neurodegeneration (1)
- neurogenesis (1)
- neurosciences (1)
- nitric oxide (1)
- nitro-fatty acids (1)
- nociception and pain (1)
- oxylipin (1)
- p53 (1)
- palmitoylation (1)
- patient safety (1)
- patient stratification (1)
- personalized medicine (1)
- pharmacogenetics (1)
- pharmacokinetics (1)
- pharmacokinetics/pharmacodynamics (PK/PD) (1)
- pharmacological tool (1)
- pharmacotherapy (1)
- phenotype (1)
- phosphorylcholine (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- piracetam (1)
- pirinixic acid (1)
- pirinixic acid derivative (1)
- polypharmacology (1)
- poorly soluble drugs (1)
- posttranslational modification (1)
- pranlukast (1)
- precipitation (1)
- premature transcript termination (1)
- presynaptic active zone (1)
- pretubulysin (1)
- prevention (1)
- product specification (1)
- programmed cell death (1)
- promastigote (1)
- prostaglandin (1)
- protein kinase inhibitor (1)
- proto-oncogene proteins c-akt (1)
- quality-by-design (1)
- receptor targeting (1)
- recurrent chromosomal translocations (1)
- regulatory requirements (1)
- relapse (1)
- resveratrol (1)
- rice bran extract (1)
- rna (1)
- secondary active transport (1)
- seizure (1)
- sensory neurons (1)
- sepsis (1)
- signal transduction (1)
- simplified media (1)
- site-directed mutagenesis (1)
- sodium-proton exchange (1)
- solubility (1)
- spinal cord (1)
- statin (1)
- stem cell niche (1)
- striatum (1)
- structure-based design (1)
- subventricular zone (1)
- succinate (1)
- supersaturation (1)
- surfactants (1)
- tetracycline (1)
- tocopherol (1)
- tocotrienol (1)
- tolerability and safety (1)
- tp63 gene (1)
- transport mechanism (1)
- transporter (1)
- triterpene acid (1)
- trkB (1)
- tumor cell adhesion (1)
- tumor cell transmigration (1)
- tumor vaccines (1)
- ubiquitin specific proteases (1)
- vitamin E (1)
- zafirlukast (1)
- β-Catenin (1)
- β-catenin (1)
- β‐hydroxybutyrate (1)
Institute
- Pharmazie (171)
- Medizin (47)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (19)
- Biochemie und Chemie (16)
- Biowissenschaften (8)
- Exzellenzcluster Makromolekulare Komplexe (6)
- Georg-Speyer-Haus (6)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (3)
- MPI für Hirnforschung (2)
- Sonderforschungsbereiche / Forschungskollegs (2)
In vivo manipulation of interleukin-2 expression by a retroviral tetracycline (tet)-regulated system
(1999)
We have used the tetracycline (tet)-regulated system as described previously to evaluate the applicability of controlled gene expression in cancer gene therapy. As a model gene, we used the human interleukin-2 (IL-2) gene, which has been placed under the transcriptional control of the tetO/promoter. Human melanoma cells were transduced by two modified retroviral tet vectors containing the transactivator regulatory unit and the IL-2 gene driven by the tetO/promoter, respectively. In the absence of tet, IL-2 expression in the target cells was stable over several months. IL-2 production was in the range of 40 U/106 cells/24 hours. A fine tuning of IL-2 expression could be achieved by culturing the transduced cells with increasing doses of tet, whereby a concentration of 500 ng/mL tet in the culture medium abrogated IL-2 expression. Most importantly for clinical application, IL-2 expression by the transduced melanoma cells could also be regulated in vivo. When nu/nu mice were inoculated with the transduced tumor cells, they failed to develop tumors. Instead, the inhibition of IL-2 expression in the transduced tumor cells by oral administration of tet led to subcutaneous tumor growth; this growth rate was comparable with the growth rate of subcutaneously inoculated untransduced parental cells. The finding demonstrates the applicability of the tet-regulated system in cancer gene therapy.
Alzheimer's disease-related mutations in the presenilin-1 gene (PS1) are leading to an elevated production of neurotoxic beta-amyloid 1-42 and may additionally enhance oxidative stress. Here, we provide in vivo evidence indicating that brains of transgenic mice expressing different human Alzheimer-linked PS1 mutations exhibit a reduced activity of two antioxidant enzymes. For this purpose, mice transgenic for human PS1 and for single and multiple PS1 mutations were generated. Mice with multiple PS1 mutations showed a significantly decreased activity of the antioxidant enzymes Cu/Zn superoxide dismutase and glutathione reductase already at an age of 3-4 months. As expected, this effect was less pronounced for the mice with a single PS1 mutation. By contrast, animals bearing normal human PS1 showed significantly elevated enzyme activities relative to non-transgenic littermate controls.
Apoptosis seems to be involved in immunosenescence associated with aging. Moreover, in lymphocytes (PBL) of patients with Alzheimer's disease, an increased susceptibility to the apoptotic pathway has been described possibly due to impaired protection of oxidative stress. Accordingly, it seemed to be of particular interest to investigate the contribution of normal aging to the susceptibility from human lymphocytes to programmed cell death. We could show that PBL from elderly individuals (>60 years) accumulate apoptosing cells to a significant higher extent in spontaneous and activation-induced cell death compared to younger controls (<35 years). Treatment with the oxidative stressor 2-deoxy-D-ribose or with agonistic-CD95-antibody pronounced this effect even more implicating a higher sensitivity to reactive oxygen species and a higher functional CD95 expression, respectively. In addition, expression of the activation markers HLA-DR and CD95 was significantly increased in CD3+-cells of aged subjects, while expression of CD25 did not seem to be affected by age. Expression of Bcl-2 was increased in aging and correlated with the number of apoptotic cells.
Many cases of early-onset inherited Alzheimer's disease (AD) are caused by mutations in the presenilin-1 (PS1) gene. Expression of PS1 mutations in cell culture systems and in primary neurons from transgenic mice increases their vulnerability to cell death. Interestingly, enhanced vulnerability to cell death has also been demonstrated for peripheral lymphocytes from AD patients. We now report that lymphocytes from PS1 mutant transgenic mice show a similar hypersensitivity to cell death as do peripheral cells from AD patients and several cell culture systems expressing PS1 mutations. The cell death-enhancing action of mutant PS1 was associated with increased production of reactive oxygen species and altered calcium regulation, but not with changes of mitochondrial cytochrome c. Our study further emphasizes the pathogenic role of mutant PS1 and may provide the fundamental basis for new efforts to close the gap between studies using neuronal cell lines transfected with mutant PS1, neurons from transgenic animals, and peripheral cells from AD patients. Copyright 2001 Academic Press.
Enhanced apoptosis and elevated levels of reactive oxygen species (ROS) play a major role in aging. In addition, several neurodegenerative diseases are associated with increased oxidative stress and apoptosis in neuronal tissue. Antioxidative treatment has neuro-protective effects. The aim of the present study was to evaluate changes of susceptibility to apoptotic cell death by oxidative stress in aging and its inhibition by the antioxidant Ginkgo biloba extract EGb761. We investigated basal and ROS-induced levels of apoptotic lymphocytes derived from the spleen in young (3 months) and old (24 months) mice. ROS were induced by 2-deoxy-D-ribose (dRib) that depletes the intracellular pool of reduced glutathione. Lymphocytes from aged mice accumulate apoptotic cells to a significantly higher extent under basal conditions compared to cells from young mice. Treatment with dRib enhanced this difference, implicating a higher sensitivity to ROS in aging. Apoptosis can be reduced in vitro by treatment with EGb761. In addition, mice were treated daily with 100mg/kg EGb761 per os over a period of two weeks. ROS-induced apoptosis was significantly reduced in the EGb761 group. Interestingly, this effect seemed to be more pronounced in old mice.
The ability to permeate accross the blood brain barrier (BBB) is essential for drugs acting on the central nervous system (CNS). Thus, systems that allow rapid and inexpensive screening of the BBB-permeability properties of novel lead compounds are of great importance for speeding up the drug discovery process in the CNS-area. We used immortalized porcine brain microvessel endothelial cells (PBMECICl-2) to develop a model for measurement of blood-brain barrier permeation of CNS active drugs. Investigation of different cell culture conditions showed, that a system using C6 astrocyte glioma conditioned medium and addition of a cyclic AMP analog in combination with a type IV phosphodiesterase inhibitor (R020-1724) leads to cell layers with transendothelial electrical resistance values up to 300 Ω.cm2. Permeability studies with U-[14C]sucroseg ave a permeability coefficient Pe of 3.24 + 0.14 × 10−4 cm/min, which is in good agreement to published values and thus indicates the formation of tight junctions in vitro.
The relevance of physiological immune aging is of great interest with respect to determining disorders with pathologic immune function in aging individuals. In recent years, the relevance of changes in peripheral lymphocytes in age-associated neurologic diseases has become more evident. Due to the lack of immunological studies, covering more than one event after mitogenic activation, we envisaged a new concept in the present study, aiming to investigate several events, starting from T cell receptor (TCR) ligation up to T cell proliferation. In addition, we addressed the question whether changes are present in the subsets (CD4, CD8) with aging. Phosphorylation of tyrosine residues declines with increasing age in CD4+ cells. Fewer levels of CD69 positive cells after 4 h mitogenic activation, altered expression of cytokines (IL2, IFN-gamma and TNF-alpha; 22 h) and lower proliferation (72 h) were determined in aging. Moreover, it could be shown that CD8+ lymphocytes react more effectively to mitogenic stimulation with reference to CD69 expression and proliferation in both age groups (<35 and >60 years old). These data indicate that T cell activation, mediated by TCR engagement, is significantly impaired in aging and both subsets are affected. However, bypassing the TCR does not fully restore T cell function, indicating that there are more mechanisms involved than impaired signal transduction through TCR only. The results will be discussed in relation to their relevance in neurodegenerative and psychiatric disorders.
As major sources of reactive oxygen species (ROS), mitochondrial structures are exposed to high concentrations of ROS and may therefore be particularly susceptible to oxidative damage. Mitochondrial damage could play a pivotal role in the cell death decision. A decrease in mitochondrial energy charge and redox state, loss of transmembrane potential (depolarization), mitochondrial respiratory chain impairment, and release of substances such as calcium and cytochrome c all contribute to apoptosis. These mitochondrial abnormalities may constitute a part of the spectrum of chronic oxidative stress in Alzheimer's disease. Accumulation of amyloid beta (Abeta) in form of senile plaques is also thought to play a central role in the pathogenesis of Alzheimer's disease mediated by oxidative stress. In addition, increasing evidence shows that Abeta generates free radicals in vitro, which mediate the toxicity of this peptide. In our study, PC12 cells were used to examine the protective features of EGb 761(definition see editorial) on mitochondria stressed with hydrogen peroxide and antimycin, an inhibitor of complex III. In addition, we investigated the efficacy of EGb 761 in Abeta-induced MTT reduction in PC12 cells. Moreover, we examined the effects of EGb 761 on ROS levels and ROS-induced apoptosis in lymphocytes from aged mice after in vivo administration. Here, we will report that EGb 761 was able to protect mitochondria from the attack of hydrogen peroxide, antimycin and Abeta. Furthermore, EGb 761 reduced ROS levels and ROS-induced apoptosis in lymphocytes from aged mice treated orally with EGb 761 for 2 weeks. Our data further emphasize neuroprotective properties of EGb 761, such as protection against Abeta-toxicity, and antiapoptotic properties, which are probably due to its preventive effects on mitochondria.
The identification of specific genetic (presenilin-1 [PS1] and amyloid precursor protein [APP] mutations) and environmental factors responsible for Alzheimer's disease (AD) has revealed evidence for a shared pathway of neuronal death. Moreover, AD-specific cell defects may be observed in many other nonneuronal cells (e.g., lymphocytes). Thus, lymphocytes may serve as a cellular system in which to study risk factors of sporadic, as well as genetic AD in vivo. The aim of our present study was to clarify whether lymphocytes bearing genetic or sporadic risk factors of AD share an increased susceptibility to cell death. Additionally we examined whether a cell typespecific vulnerability pattern was present and how normal aging, the main risk factor of sporadic AD, contributes to changes in susceptibility to cell death. Here, we report that lymphocytes affected by sporadic or genetic APP and PS1 AD risk factors share an increased vulnerability to cell death and exhibit a similar cell type-specific pattern, given that enhanced vulnerability was most strongly developed in the CD4+ T-cell subtype. In this paradigm, sporadic risk factors revealed the highest impact on cell type-specific sensitivity of CD4+ T cells to apoptosis. In contrast, normal aging results in an increased susceptibility to apoptosis of both, CD4+ and CD8+ T cells.
Background: In rat, deafferentation of one labyrinth (unilateral labyrinthectomy) results in a characteristic syndrome of ocular and motor postural disorders (e.g., barrel rotation, circling behavior, and spontaneous nystagmus). Behavioral recovery (e.g., diminished symptoms), encompassing 1 week after unilateral labyrinthectomy, has been termed vestibular compensation. Evidence suggesting that the histamine H3 receptor plays a key role in vestibular compensation comes from studies indicating that betahistine, a histamine-like drug that acts as both a partial histamine H1 receptor agonist and an H3 receptor antagonist, can accelerate the process of vestibular compensation. Results: Expression levels for histamine H3 receptor (total) as well as three isoforms which display variable lengths of the third intracellular loop of the receptor were analyzed using in situ hybridization on brain sections containing the rat medial vestibular nucleus after unilateral labyrinthectomy. We compared these expression levels to H3 receptor binding densities. Total H3 receptor mRNA levels (detected by oligo probe H3X) as well as mRNA levels of the three receptor isoforms studied (detected by oligo probes H3A, H3B, and H3C) showed a pattern of increase, which was bilaterally significant at 24 h post-lesion for both H3X and H3C, followed by significant bilateral decreases in medial vestibular nuclei occurring 48 h (H3X and H3B) and 1 week post-lesion (H3A, H3B, and H3C). Expression levels of H3B was an exception to the forementioned pattern with significant decreases already detected at 24 h post-lesion. Coinciding with the decreasing trends in H3 receptor mRNA levels was an observed increase in H3 receptor binding densities occurring in the ipsilateral medial vestibular nuclei 48 h post-lesion. Conclusion: Progressive recovery of the resting discharge of the deafferentated medial vestibular nuclei neurons results in functional restoration of the static postural and occulomotor deficits, usually occurring within a time frame of 48 hours in rats. Our data suggests that the H3 receptor may be an essential part of pre-synaptic mechanisms required for reestablishing resting activities 48 h after unilateral labyrinthectomy.